DT402
Science of DT402
DT402 is the R-enantiomer of MDMA and is under development to target the core symptoms of autism spectrum disorder (ASD), specifically addressing social communication challenges. In preclinical studies, DT402 has shown promising prosocial effects with a potentially superior tolerability profile compared to both racemic MDMA and the S-enantiomer.
Clinical Data
DT402, or R(-)-MDMA, is under development to treat the core symptoms of ASD
Results from preliminary clinical studies suggest DT402 is well-tolerated and is pharmacologically active with a mechanism that could enhance social and communication skills in people with ASD. Preclinical study results of DT402 in animal models demonstrate positive effects on social functioning, which suggests that DT402 may have enhanced pro-social effects with potentially reduced side effects compared to MDMA1:
DT402 for ASD
Lead candidate advancing into Phase 2a study in Autism Spectrum Disorder
Having completed a Phase 1 single-ascending dose study that characterized the safety, tolerability, pharmacokinetics and pharmacodynamics of DT402 in healthy adult volunteers, we have initiated a Phase 2a study. This study is a single-dose, open label design assessing early signals of efficacy in up to 20 adult participants with ASD. The objectives and endpoints of the study are designed to characterize the pharmacodynamics and clinical effects of DT402 in adults with ASD across multiple functional domains.
Be a part of what’s next
We are working to turn breakthroughs in the lab into breakthroughs in the lives of people who are most in need. By participating in a clinical trial, you may play a crucial role in improving care and developing potential new treatments that may one day change lives, including your own.
Precise science. Boundless impact.
- “MM402 demonstrates better efficacy than S(+)-3,4-MDMA or (+)-3,4-MDMA in Fmr1 knockout mice, an animal model of autism spectrum disorder.” Presented at ECNP 2023. Data from “stranger” portion of “Duration in the arena” data.
- Pitts EG, Curry DW, Hampshire KN et al. 2018, Psychopharmacology; 235(2):377-392.